Abstract
Introduction: This is a retrospective study of the effectiveness of Amicar in decreasing perioperative blood loss and the need for transfusion in same-day anterior (ASF) and posterior spinal fusion (PSF) with segmental spinal instrumentation (SSI) in idiopathic scoliosis. Preliminary prospective, prospective randomized double-blind and fibrinogen studies have demonstrated Amicar to be effective in decreasing perioperative blood loss in idiopathic scoliosis surgery. Increased fibrinogen secretion is a possible explanation.
Methods. Amicar is administered at 100mg/kg over 15 min not to exceed 5 grams at anesthesia induction. Maintenance is 10mg/kg/hr until wound closure. There were three study groups: Group 1, (n=15), no Amicar; Group 2, (n=27), Amicar for the PSF only; and Group 3, (n=16), Amicar for both ASF and PSF.
Results. The total perioperative blood loss (estimated intraoperative blood loss for the ASF and PSF procedures, measured suction drainage and measured chest tube drainage) and the transfusion (autologous and bank blood) requirements were: Group 1, 3807±105ml and 3.1±1.5 units; Group 2 2080±659ml and 1.9±0.9 units; and Group 3 2183±851ml and 1.0±0.8 units.
Conclusions. Amicar appears highly effective in decreasing perioperative blood loss and transfusion requirements in same-day ASF, PSF, with SSI in idiopathic scoliosis. This results in less preoperative autologous blood donation, blood transfusion, costs, and potential transfusion-related complications. It appears to be most effective in decreasing intraoperative PSF blood loss and chest tube drainage. It had no effect during the ASF. We now recommend that it be used for the posterior procedure only.
Correspondence should be addressed to: Dr Caroline Goldberg, The Research Centre, Our Lady’s Children’s Hospital Crumlin, Dublin 12, Ireland.
